INTRODUCTION
============

The report of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) enzyme in 1996 and its subsequently determined critical role in the pathogenesis of thrombotic thrombocytopenic purpura (TTP) has enabled biomarker confirmation for the clinical diagnosis of TTP \[[@sfy066-B1]\]. The failure to detect ADAMTS13 activity (upon which the clinical diagnosis of TTP is confirmed) in individuals with absolute or relative thrombocytopenia and microangiopathic hemolysis \[the classic definition for a thrombotic microangiopathy (TMA)\] and in whom shiga toxin *Escherichia coli* (STEC) HUS has been excluded has resulted in an increasing awareness of the eclectic clinical presentations of aHUS \[[@sfy066-B4]\]. It is now clear that patients with aHUS have been misdiagnosed as having TTP and that TTP is associated with more severe thrombocytopenia and less severe acute kidney injury than aHUS. Individuals with a platelet count \>30 000/mL^3^ and creatinine \>1.7 mg/dL have only about a 3% chance of having TTP \[[@sfy066-B8]\]. In contrast, aHUS may present along the entire spectrum of platelet counts and renal function \[[@sfy066-B9]\].

As significant as the growth of our knowledge has been over the past decade vis-à-vis distinguishing aHUS versus TTP, clinicians are now beginning to recognize that clinical scenarios of a TMA complicating another disease or disorder, in which a TMA is only infrequently seen, are associated with poor clinical outcomes. These conditions include autoimmune diseases \[e.g. systemic lupus erythematosus (SLE)\], bone marrow transplant complicated by graft-versus-host disease (GVHD), malignant hypertension and certain infections (e.g. Parvo B19 and human immunodeficiency virus). In these clinical settings, complement activation is often present. A TMA has rarely been seen with certain medications (e.g. calcineurin inhibitors, chemotherapeutic agents mitomycin-C and gemcitabine, platelet aggregation inhibitors clopidogrel and ticlopidine and angiogenesis inhibitor bevacizumab). These drugs are known to have the potential to directly injure endothelia \[[@sfy066-B10]\]. Thus the next challenges are understanding what, if any, clinical and biomarker findings can be applied to make a diagnosis of aHUS, especially when a TMA occurs in the setting of a disease in which complement dysregulation is present, and whether it is appropriate to use the appellation aHUS for a time-limited, discrete pathophysiologic disorder, as in GVHD. Although eculizimab therapy is approved for complement-mediated aHUS \[[@sfy066-B18]\], when the phenotypic expression of aHUS occurs in other established disorders associated with complement activation and direct endothelial injury \[e.g. SLE and GVHD\] and does not resolve with treatment of the underlying disease, there may be a role for a time-limited course of eculizimab.

This review will address the pathogenesis, clinical presentation, diagnosis and management of aHUS.

PATHOGENESIS OF COMPLEMENT-MEDIATED AHUS
========================================

In 1954, 58 years after the discovery of the classical pathway of complement, Louis Pillimer reported his findings on an 'alternate pathway' of complement activation \[[@sfy066-B19]\]. Although initially met with fierce criticism, his data were corroborated in 1967 \[[@sfy066-B20], [@sfy066-B21]\]. In 1981, all the proteins in the alternative pathway (AP) were identified \[[@sfy066-B22]\]. The AP of complement activation is now appreciated to be the most atavistic of the three activating pathways of the proximal cascade (the lectin pathway was discovered in 1976) \[[@sfy066-B23]\]. Unique to the AP is that constitutively it is 'always on'---with a default setting of attack \[[@sfy066-B26]\].

Initiation of the complement cascade, the proximal step, begins with activation of C3. Unlike the classical and lectin pathways, activation is not based on pattern recognition molecules, as it occurs with foreign antigens that gain access to the internal milieu of the organism \[[@sfy066-B22], [@sfy066-B27]\]. The 'always on' default setting of the AP is due to a thioester bond within C3 that in plasma water results in a conformational change of this zymogen \[[@sfy066-B26]\]. Although existing in an ephemeral state (milliseconds), the hydrolyzed C3 allows the binding of factor B, followed by the activation of factor B by factor D. The activated fragment of factor B (Bb) remains bound to the C3 thioester hydrolyzed protein (the 'tickover' process). This results in a labile C3 convertase that activates adjoining C3 proteins to produce C3b, a more stable product than hydrolyzed C3, upon which identical steps of factor B and factor D activation occur to produce a membrane-bound C3 convertase (further stabilized by properdin) and C3a, a weak anaphylatoxin \[[@sfy066-B19], [@sfy066-B30]\]. In addition to forming C3 convertase, C3b indiscriminately opsonizes anionic surfaces---host or pathogen \[[@sfy066-B30]\]. The other fragment of factor B activation, Ba, is released into the plasma. Plasma Ba can be measured and reflects proximal activation of the complement cascade \[[@sfy066-B36]\] ([Figure 1](#sfy066-F1){ref-type="fig"}).

![Initiation of complement cascade begins with activation of C3. Activation occurs via the 'tickover' process of the alternative pathway, the classical pathway and lectin pathway. Enzymatic cleavage of CFB bound to C3(H20) or C3b by complement Factor D results in activation of CFB to C3(H20)Bb or C3bBb, and Ba (a marker of proximal complement activation). C3bBb is stabilized by Properdin protein.](sfy066f1){#sfy066-F1}

The downstream activation of the complement cascade---the terminal pathway---commences following the binding of an additional C3b protein to C3 convertase (C3bBb) to form C5 convertase (C3bBbC3b). C5 convertase activates C5 by cleaving it into C5a and C5b. C5a is a potent anaphylatoxin, with pro-thrombotic and pro-inflammatory properties, and also activates endothelial cells and leukocytes. C5b is the nidus upon which C6, C7, C8 and multimers of C9 attach to produce C5b-9, the membrane attack complex (MAC) \[[@sfy066-B19], [@sfy066-B37]\]. In addition to pro-inflammatory and pro-thrombotic properties, MAC activates leukocytes, endothelial cells and platelets and destroys the cell it is nondiscriminately attached to---host or pathogen---as a consequence of its forming a channel through the cell membrane. Cell lysis ensues as extracellular calcium entry disrupts intracellular homeostasis, resulting in mitochondrial failure. Cell lysis occurs as early as 30 min following assembly of the MAC \[[@sfy066-B19]\].

Crosstalk between the coagulation system and the complement cascade has been recognized with the demonstration of a thrombin-dependent activation of C5 that is both independent of and dependent upon C5 convertase \[[@sfy066-B38]\] ([Figure 2](#sfy066-F2){ref-type="fig"}).

![Complement cascade and complement regulatory proteins (CRP). CRP modulate the 'tickover' process of alternative pathway activation and protect host cells from activated complement proteins generated via all three pathways. Thrombin independently activates C5 in conjunction with C5 convertase. C3b -- activated C3; CFB -- complement factor B; CFD -- complement factor D; C3bBb -- C3 convertase; C3bBbC3b -- C5 convertase; CRP may inactivate C3b, prevent binding of CFB to C3b, or accelerate decay of C3 convertase and C5 convertase. CRP regulation: I -- inactivation C3 to C3i; II -- inhibit binding of CFB to C3b; III -- accelerate decay of C3 convertase; IV -- accelerate decay of C5 convertase. CFH (complement factor H) -- regulatory functions I, II, III, IV; CFI (complement factor I) -- regulatory function I as cofactor for membrane cofactor protein (MCP) and thrombomodulin (TBMD).](sfy066f2){#sfy066-F2}

Complement regulatory proteins (CRPs) were first discovered in 1981 \[[@sfy066-B22], [@sfy066-B31]\]. They comprise approximately half of all proteins in the complement cascade. They have two roles. The first is to modulate the 'always on' feature of the AP to keep the system primed ('tickover process') but not fully activated (\<1% of total plasma C3 is activated hourly) \[[@sfy066-B26], [@sfy066-B29], [@sfy066-B39]\]. By permitting the proximal activation of complement to be primed, the regulatory proteins allow near instantaneous amplification of the AP once a perturbation in the internal milieu (by any of the three activating processes) is detected. The second important function of the regulatory proteins is to ensure that once the complement cascade is amplified, the potent end products (C5a and C5b-9) are limited to interacting with pathogens and nonhealthy host cells \[[@sfy066-B40]\]. The regulatory proteins form an overlapping protective matrix for host endothelia. The regulatory proteins currently recognized as important in the pathogenesis of aHUS are complement factor H (CFH), complement factor I (CFI), membrane cofactor protein (MCP or CD46) and thrombomodulin \[[@sfy066-B4], [@sfy066-B29], [@sfy066-B33], [@sfy066-B41]\]. Loss-of-function mutations of these proteins, polymorphisms in CFH, fusion proteins of CFH, antibodies against CFH and deletions of CFH-related proteins have been associated with aHUS \[[@sfy066-B5], [@sfy066-B6], [@sfy066-B42], [@sfy066-B43]\]. Dysregulation of the AP can also arise from gain-of-function mutations in C3 and complement factor B (CFB) and are also associated with aHUS \[[@sfy066-B6]\]. In this pathogenic setting, CRPs are normal but ineffective in regulating the complement cascade due to the formation of 'super' C3 and C5 convertases ([Figure 2](#sfy066-F2){ref-type="fig"}).

CLINICAL PRESENTATION
=====================

In contrast to the pentad descriptors of TTP (TMA---thrombocytopenia and Coombs negative hemolytic anemia, neurologic and renal findings and fever), until recently the clinical picture ascribed to aHUS was TMA and renal involvement \[[@sfy066-B44]\]. Data over the last 10--15 years have upended this decades-long misconception and have also resulted in our appreciation of the equally long misconception that aHUS is primarily a disease of children \[[@sfy066-B4], [@sfy066-B7], [@sfy066-B44], [@sfy066-B49]\].

As befits a syndrome that reflects disruption of the modulators and proteins of complement activation and host cell protection, the clinical manifestations of aHUS may be protean and involve, with different frequencies, all organ systems. These presentations include:

*Hematologic---*Absolute or relative thrombocytopenia along with a microangiopathic hemolytic anemia \[schistocytes, increased lactate dehydrogenase (LDH), decreased haptoglobin and decreased hemoglobin\] are frequently, but not invariably, observed at the time of presentation. Further complicating the diagnosis is the recognition that not all the findings of a microangiopathic anemia need be observed at presentation or throughout the clinical presentation (e.g. no schistocytes). It is appreciated that a renal-limited form of aHUS can occur \[[@sfy066-B4], [@sfy066-B6], [@sfy066-B7]\].

*Renal---*Although acute kidney injury is the most common finding at initial presentation, isolated proteinuria or hematuria may occur \[[@sfy066-B4], [@sfy066-B6], [@sfy066-B7]\]. Patients may present along the entire spectrum of kidney injury, including the need for renal replacement therapy. Nephrotic range proteinuria is not infrequent. Commonly ascribed in pediatric patients with aHUS arising from mutations in diacyl glycerol kinase epsilon (DGKE) that presents within the first year of life, nephrotic range proteinuria is found across the age spectrum \[[@sfy066-B53]\]. Although the pathogenesis of DGKE was initially described as a complement-independent process, complement involvement, albeit rare, has subsequently been reported \[[@sfy066-B55]\]. Complement-mediated podocyte injury has recently been reported in patients with and without DGKE aHUS and offers a pathogenic mechanism for nephrotic range proteinuria \[[@sfy066-B54]\]. The classic histologic findings seen in aHUS include platelet and fibrin deposition in capillaries, endothelial cell injury, proliferation of the myocyte layer, electron lucent subendothelial space widening, double contouring of glomerular capillary walls, endotheliosis and negative immunofluorescence findings for immunoglobulins. Histologic findings of aHUS have also been reported in patients with previously diagnosed other forms of glomerulonephritides who subsequently develop nephrotic range proteinuria \[[@sfy066-B54]\].

*Gastrointestinal---*Gastrointestinal involvement most commonly manifests with diarrhea, which may be bloody, and occurs in up to 30% of individuals. Additional findings include nausea and vomiting, pancreatitis and hepatic and colonic involvement \[[@sfy066-B5], [@sfy066-B44], [@sfy066-B51]\].

*Central nervous system (CNS)---*CNS involvement, long thought to be solely within the purview of TTP, is now a well-recognized occurrence in aHUS. Presentations include confusion and encephalopathy, stroke and seizures \[[@sfy066-B6], [@sfy066-B7], [@sfy066-B51], [@sfy066-B52]\].

*Respiratory tract---*Next to diarrhea and gastroenteritis, upper respiratory tract infection is the most common condition on presentation of aHUS \[[@sfy066-B6]\]. Lower respiratory tract involvement, including pulmonary hypertension, has been reported \[[@sfy066-B51]\]. In contrast to TTP, pulmonary hemorrhage occurs in aHUS \[[@sfy066-B57]\].

*Cardiovascular (CV)---*CV involvement occurs in ∼3--10% of patients and manifests with myocardial infarction, myocarditis and dilated or ischemic cardiomyopathy. Peripheral gangrene and large vessel disease involving the carotid, cerebral, subclavian and pulmonary arteries have been reported in the pediatric population. Hypertension is frequently seen in patients with aHUS \[[@sfy066-B58], [@sfy066-B59]\]. Malignant hypertension occurs in aHUS \[[@sfy066-B14], [@sfy066-B60]\].

*Skin---*Dermatologic involvement in aHUS is rare. Purpuric and ulcerative or necrotic skin lesions have been reported \[[@sfy066-B61]\].

*Ocular---*Ophthalmologic involvement is another rare manifestation of aHUS. Retinal artery occlusion and serous retinal detachment have been reported \[[@sfy066-B62]\].

DIAGNOSIS AND DEFINITION
========================

In the absence of a specific test, at present, aHUS is a clinical diagnosis of a complement-mediated TMA that rests upon the exclusion of TTP and STEC infection. The recent appreciation of the protean organ system involvement that can occur in aHUS stands in distinct contrast to earlier beliefs. In this context, ADAMTS13 testing in aHUS reveals an activity percentage that is more than the lowest detectable value for the reference lab performing the analysis (\>5--10%) \[[@sfy066-B6], [@sfy066-B7], [@sfy066-B44]\]. Indeed in aHUS, ADAMTS13 activity percentages can range from normal values to markedly reduced levels \[[@sfy066-B65], [@sfy066-B66]\]. Antiphospholipid antibody syndrome (APS) is also in the differential diagnosis of a complement-mediated TMA \[[@sfy066-B67]\]. [Figure 3](#sfy066-F3){ref-type="fig"} offers an approach to the diagnosis.

![Proposed algorithm to distinguish primary from secondary aHUS. This algorithm will require validation of markers of proximal and terminal complement activation. Secondary aHUS includes autoimmune disease, GVHD, medications, malignant hypertension, malignancy and glomerular disease.](sfy066f3){#sfy066-F3}

Occasionally the clinician will care for a patient where the diagnosis of aHUS is not clear-cut \[[@sfy066-B44], [@sfy066-B68]\].

An ever-increasing, albeit small number of series and case reports have illustrated that treating a TMA component in systemic diseases not usually associated with a TMA (e.g. lupus nephritis, GVHD complication of stem cell transplant and pregnancy) as aHUS (when the differential diagnoses have been excluded) can result in significantly improved outcomes when treating the primary disease fails to resolve the TMA \[[@sfy066-B11], [@sfy066-B69]\]. This has recently been described as a phenotypic expression of aHUS without the risk of recurrence as occurs in 'classic' or 'primary' aHUS as it is presently understood (vida infra) \[[@sfy066-B73]\]. Current opinion does not view the finding of a TMA (without supporting evidence for STEC, TTP or APLS) in these complement-dysregulated conditions as aHUS \[[@sfy066-B44]\]. Yet this opinion does not take into account either the otherwise poor prognosis of these patients without aHUS-specific therapy or the beneficial reports of patients who are treated for the presumed diagnosis of aHUS. It is in this context that a narrowly defined diagnosis of aHUS limits treatment options and is potentially injurious to the patient. Illustrative of the uncertainty regarding the application of the appellation, secondary aHUS is found in a paper that examined potential genetic risk factors in aHUS relapse following discontinuation of eculizimab therapy (vida infra) \[[@sfy066-B74]\].

In the interim, utilizing our understanding of the pathogenesis of complement-mediated aHUS and the response to eculizimab therapy these complicated patients manifest may better guide the clinician to a diagnosis of an aHUS component to the underlying disease state.

Paramount to the diagnosis of aHUS is the dysregulation of the AP of complement activation. However, detection of genetic abnormalities or antibodies to CFH is not a universal finding in aHUS---and has been reported in 50--70% of patients \[[@sfy066-B4], [@sfy066-B6], [@sfy066-B7], [@sfy066-B44]\]. Thus does the inability to detect a genetic mutation reflect our present diagnostic limitations to detect all disruptors of complement homeostasis? An affirmative answer was demonstrated in a recent report that described intronic mutations in the *DGKE* gene, when standard genomic testing failed to do so \[[@sfy066-B75]\]. In addition, data have also demonstrated that patient outcomes are comparable whether or not genetic mutations are detected \[[@sfy066-B6], [@sfy066-B50]\]. These observations are consistent with the belief that there exist undiagnosed genetic predispositions to the pathogenesis of complement-mediated aHUS \[[@sfy066-B76]\].

However, I believe that aHUS due to dysregulation of the AP of complement can also manifest phenotypically without a genetic predisposition \[[@sfy066-B73]\]. The clinical scenarios described (e.g. lupus nephritis and GVHD following stem cell transplant) provide the basis for this hypothesis. These disorders can be associated with marked complement activation and are associated with direct endothelial damage \[[@sfy066-B11], [@sfy066-B69], [@sfy066-B72], [@sfy066-B77]\]. Importantly, direct endothelial damage is a primary and additional activator of the AP of complement \[[@sfy066-B22], [@sfy066-B78], [@sfy066-B79]\]. This further amplifies complement activation, resulting in a complement storm that overwhelms otherwise intact CRPs. In this setting, therapy directed solely at the underlying disease process may be insufficient to break the cycle of ongoing endothelial cell damage. Thus a two-prong therapeutic approach may offer a better treatment regimen. When this approach has been reported, the results have been encouraging \[[@sfy066-B11], [@sfy066-B69]\] ([Figure 3](#sfy066-F3){ref-type="fig"}). As described in the next section, the utility of known biomarkers to indicate activation of proximal and terminal complement activation remains a nascent field of inquiry.

As will be discussed in the last section of this review, this methodological approach to treatment need not obligate an individual to long-term eculizimab therapy.

NATURAL HISTORY, BIOMARKER TESTING AND TREATMENT
================================================

In 2013, eculizimab (Soliris) received expedited approval from the US Food and Drug Administration (FDA) for the treatment of aHUS to inhibit complement-mediated TMA \[[@sfy066-B18]\]. Following additional required prospective studies in pediatric and adult populations, in 2015 the FDA gave standard approval for eculizimab therapy for aHUS. It is presently the only FDA-approved therapy for aHUS. Eculizimab is a humanized monoclonal antibody that inhibits the formation of terminal complement proteins C5a and C5b-9. Eculizimab binds with high affinity to C5 complement protein, thus preventing downstream complement activation \[[@sfy066-B80]\].

Prior to the availability of eculizimab therapy, outcomes were poor in patients with aHUS treated with plasma-based therapy \[[@sfy066-B4]\]. Despite the historical use of plasmapheresis in the treatment of aHUS, there has never been a prospective trial to evaluate the usefulness of expensive plasma-based therapies (plasma infusion and plasmapheresis) \[[@sfy066-B4], [@sfy066-B81]\]. Although reports have demonstrated short-term benefits (months) primarily in thrombocytopenia and anemia, there are no data that show a long-term renal benefit of plasma-based therapy in aHUS \[[@sfy066-B4]\].

During the first presentation of aHUS, death or end-stage renal disease was reported in up to 40% of patients. Nearly 80% of patients with aHUS died, required renal replacement therapy or had chronic kidney disease within 3 years after diagnosis. These poor short- and long-term outcomes occurred on plasma-based therapy. Patients in whom a genetic mutation was not detected were reported to have short-term (months) and long-term (5- to 10-year) outcomes comparable with patients with a genetic mutation. Historical outcomes for children who develop aHUS from an MCP mutation have revealed an ∼20% rate of death or end-stage renal disease at 5--10 years \[[@sfy066-B4]\].

The introduction of eculizimab has transformed the outcome of this disease and the quality of life of those afflicted \[[@sfy066-B80]\]. In contrast to plasma-based therapies, the TMA response to eculizimab therapy has reflected the dramatic inhibition of terminal complement activation. Following initiation of eculizimab therapy in adults, the median time for the platelet count and LDH levels to reach normal range was 7 and 28 days, respectively \[[@sfy066-B80], [@sfy066-B81], [@sfy066-B83]\], and in children it was 7 and 48 days, respectively \[[@sfy066-B84]\]. Hematological normalization occurred in ∼75% of adult patients at week 26 of therapy and in nearly 90% of adult patients at 52 and 104 weeks \[[@sfy066-B80], [@sfy066-B83]\]. In a pediatric trial, hematologic normalization occurred in 82% of children after a median of 55 days \[[@sfy066-B84]\].

In the pediatric and adult trials, ∼80% of patients who required renal replacement therapy at presentation and who began eculizimab treatment within a month following diagnosis of aHUS were able to come off dialysis. Pediatric patients experienced a mean improvement in eGFR from baseline of 64 mL/min/1.73 m^2^ and in adult patients the mean change from baseline was +30 mL/min/1.73 m^2^ at 27 weeks of eculizimab therapy. The 2-year follow-up of aHUS adult patients on eculizimab has demonstrated ongoing improvement in renal function (eGFR +33 mL/min/1.73 m^2^) \[[@sfy066-B80], [@sfy066-B83], [@sfy066-B84]\].

The duration of treatment is unclear \[[@sfy066-B83]\].

Withdrawal of eculizimab has been reported. In the largest series reported to date, where 108 patients enrolled in the French aHUS registry between 2010 and 2014 who received eculizimab and in whom eculizimab was discontinued were followed \[[@sfy066-B74]\]. At the time of this report, 11 patients were receiving renal replacement therapy and two patients had died. Renal transplant recipients and patients with secondary aHUS (autoimmune disease, drugs, infection or cancer) were excluded from consideration to have eculizimab withdrawn. The decision to stop eculizimab was made by the treating physician. Six patients were lost to follow-up. Of the 38 patients in whom eculizimab was withdrawn, CFH and MCP mutations were discovered in 11 (29%) and 8 (21%) of patients, respectively. C3 and a CFI variant were each noted in one (2.5%) patient. No complement gene variants were detected in 16 (42.5%) patients. Relapse was noted in 8 of 11 (72%) patients with CFH mutations and in 4 of 8 (50%) patients with MCP mutations. Relapse was not observed in the 16 patients with no identified gene variants. The median time to relapse was 7.5 months (range 3--29). Eculizimab was restarted within 48 h in all patients with return of renal function to pre-eculizimab discontinuation values. No biomarker data were obtained. The second paper reported on the discontinuation of eculizimab in 10 of 22 patients with aHUS who were treated with eculizimab. All 10 patients had an identified complement abnormality. Relapse occurred in 3 of the 10 patients. Each patient had a CFH mutation. In each patient, relapse occurred within 6 weeks of the last dose of eculizimab. Eculizimab was immediately resumed in all three patients and all patients completely recovered \[[@sfy066-B85]\]. Data reported from the clinical trials of eculizimab reveal a recurrence rate following discontinuation of therapy of 20% (12/61 patients) \[[@sfy066-B86]\]. This paper also reported on patients registered in the global aHUS registry. In patients \<18 years of age, 28 patients (24%) had eculizimab discontinued and recurrence resulted in reinitiation of eculizimab in 7 patients (25%), whereas 48 adult patients (27%) discontinued therapy, with resumption of eculizimab in 5 patients (10%) \[[@sfy066-B86]\]. Recurrence occurred in 16 of 52 patients (31%) in published case reports reviewed by the authors. The authors note that cessation of eculizimab can increase TMA recurrence and that the timing and severity are unforeseeable.

At present, there are no biomarker data to permit the identification of patients who are at risk to recur. Additional clinical data are needed to assess recurrence risk in patients in whom no complement gene mutation is detected since historical data reveal morbidity and mortality outcomes comparable with patients with complement gene mutations \[[@sfy066-B4]\]. There are no data that examine withdrawal of eculizimab in secondary aHUS or in the renal transplant recipient who develops aHUS.

In addition to the clinical profile and genetic profile of the patient, judicious withdrawal of eculizumab will be aided when biomarker and complement data in controlled studies become available.

A recent exploratory study evaluated complement biomarker data in adult patients with aHUS treated with short-term plasmapheresis \[[@sfy066-B36]\]. Of note, irrespective as to whether LDH, haptoglobin and/or platelet counts improved with plasmapheresis or remained unchanged, biomarker evaluation of baseline elevated proximal (plasma Ba) and terminal (urine C5a and urine C5b-9 excretion) complement activation remained unchanged. It is important to highlight that any improvement seen in platelet count, haptoglobin and LDH when patients with aHUS were treated short term with plasmapheresis was not associated with an improvement in the pathogenic mechanism, that is, dysregulation of the AP of complement activation, of aHUS. Until biomarker and complement testing become routinely available to diagnose and assess treatment response to eculizumab, the use of LDH, haptoglobin and platelet count levels and renal response (creatinine and urinalysis) remain the sole means to evaluate treatment response.

In this article, eculizumab was initiated following short-term plasmapheresis therapy. Immediately following the first dose of eculizumab significant improvements in urine C5a and urine sC5b-9 values were noted in all patients. Levels of these terminal complement biomarkers were comparable with healthy normal volunteers by 2.5 weeks and remained so for the duration of the study (52 weeks). Consistent with the mechanism of action of eculizumab, plasma Ba levels did not normalize. By 6 weeks after the first dose of eculizumab, proximal complement activation was reduced by 30% and persisted over the year time frame. That plasma Ba levels did decrease with eculizumab is a reflection of the abrogation of the positive feedback of endothelial damage on AP activation, the underlying pathogenesis of aHUS with ongoing disruption of complement regulation and presumably improvement in renal function (data were not provided to determine the extent of this factor) \[[@sfy066-B22], [@sfy066-B36], [@sfy066-B78]\]. At present, reliable and sensitive markers of proximal and terminal activation and direct comparison of serum and urine markers are not available \[[@sfy066-B87]\]. aHUS is a clinical diagnosis. Once TTP and shiga toxin HUS are excluded (which should be possible by 48 h), therapy with eculizimab is begun. Genetic testing is neither required nor indicated to initiate therapy.

Since terminal complement activation is required for encapsulated organisms (i.e. meningococcal), all patients must be vaccinated with meningococcal vaccinations. In addition to the quadrivalent vaccine that protects against serogroups A, C, W and Y, the FDA has recently approved a meningococcal vaccine for serogroup B \[[@sfy066-B88]\]. In light of the risks associated with aHUS if therapy with eculizimab is delayed, the standard of practice is to administer the vaccination as soon as the decision is made to begin eculizimab therapy. Patients receive penicillin or ciprofloxacin prophylaxis for the subsequent 2 weeks it takes for antibody production and protection to be generated. Since immunization against meningococcal infection is not 100%, some physicians maintain antibiotic prophylaxis. Advisory Committee on Immunization Practices vaccination guidelines regarding pneumococcal vaccination and *Haemophilus influenzae* must be followed.

Eculizimab is a category C drug \[[@sfy066-B18]\].

Notwithstanding the aforementioned lack of controlled trials in the use of plasmapheresis in aHUS, aHUS arising from anti-CFH antibodies has been reported to respond to plasmapheresis and immunosuppressive therapy \[[@sfy066-B89]\]. As seen in the eculizimab trials, renal recovery was associated with earlier initiation of therapy---in this article---plasmapheresis. However, renal recovery was noted in 71% of children versus 82% of children in the eculizimab trial \[[@sfy066-B83], [@sfy066-B89]\]. It is not known whether the use of eculizimab would have resulted in outcomes different than seen with plasmapheresis and immunosuppressive therapy.

In those cases where eculizimab is unavailable or not tolerated, liver transplantation, with the attendant risks, appears curative in aHUS when it arises from soluble CRP or complement protein mutations \[[@sfy066-B4]\].

The treatment of this ultrarare disease is expensive. Dosing is weight based. In adults, the standard annual maintenance cost approaches \$600 000 \[[@sfy066-B85]\].

TMA IN SLE, GVHD, MALIGNANT HYPERTENSION, OTHER DISEASES AND PREGNANCY
======================================================================

As previously stated, TMA has been infrequently or rarely associated with or ascribed to other diseases, including SLE, GVHD complicating bone marrow transplant, malignant hypertension, pregnancy (intra- and postpartum), sepsis and certain medications. These observations have been known for decades. In addition, recent basic research and clinical reports of patients with APS and catastrophic APS (CAPS) lend further support to the role of complement activation and direct endothelial damage (as opposed to cell membrane injury caused by the MAC) in the pathogenesis of TMA when present in these disorders \[[@sfy066-B90]\]. These case reports illustrate the potential efficacy of eculizimab when plasmapheresis and other immunosuppressive therapies are not effective. Until additional means of diagnosing aHUS become available, the significance of a concomitant TMA is a conundrum. Nevertheless, when a TMA coexists in a disease or disorder where direct endothelial damage is present and marked complement activation is felt to be present that is unresponsive to conventional therapy, especially when there is ongoing or new renal, cardiac or CNS events, it behooves the clinician to consider the diagnosis of secondary aHUS.

If genetic testing reveals a complement protein mutation or antibody then, in retrospect, primary aHUS was unmasked by the presenting disorder. But, as noted earlier, since this takes time and only ∼60% of patients have a detectable gene variant, the clinician's ultimate decision to consider secondary aHUS must be based on the clinical picture and the best interest of the patient.

In addition to the examples noted above, complement is involved in a wide range of inflammatory and infectious disorders. Complement is part of our innate immune system \[[@sfy066-B19]\]. Thus a common link between aHUS and these other conditions is complement activation. When complement activation is marked---that is, a complement storm---and endothelial damage is present as a consequence of the underlying condition, a pathogenic picture occurs that parallels that seen in primary aHUS. In this construct, the phenotypic expression of aHUS can occur in the absence of genetic mutations of proteins and regulatory proteins. Undoubtedly other modifying factors are present to account for this uncommon phenotypic expression of secondary aHUS. Another difference from primary aHUS would be the chronicity and duration of therapy required. 'Classical' or primary aHUS is defined as a primary dysregulation of AP activation. Although this suggests the need for long-term therapy in these patients, as previously described, there are presently limited data to assess in whom eculizimab therapy may be stopped \[[@sfy066-B74], [@sfy066-B85], [@sfy066-B86]\]. In contrast, the therapy for secondary aHUS should be required only until the etiology for the direct endothelial cell damage and marked complement activation has resolved. In this unique clinical setting a two-prong therapeutic approach should be efficacious: (i) treating the underlying disorder (e.g. SLE, GVHD and malignant hypertension) in order to halt direct endothelial cell damage that directly activates AP of complement and (ii) treating the secondary aHUS component to abrogate the profound complement amplification that further injures endothelial cells. After sufficient time has passed on eculizimab treatment (most likely months) to allow for endothelial cell healing to take place and the patient has clinically improved, the availability of biomarker data and proximal and terminal complement functional testing will allow the clinician to distinguish between a primary aHUS unmasked by the underlying disease and a secondary aHUS. Until these tests become available the distinction between primary and secondary aHUS remains a clinical judgment.

Our present understanding of aHUS would predict that if the aHUS associated with another disease or disorder was due to an unmasking of a genetic predisposition to aHUS, that is, primary aHUS, there would be evidence of ongoing evidence of AP activation, that is, demonstration of continued proximal complement activation \[[@sfy066-B7]\]. Whether other laboratories corroborate the exploratory data that show abnormal plasma Ba levels to be highly sensitive in patients with 'primary' aHUS and whether this can be meaningfully interpreted in the setting of renal injury remains to be seen \[[@sfy066-B7]\]. Direct endothelial cell evaluation (i.e. biopsy) of proximal and terminal complement biomarker activation may be necessary to assess ongoing complement activity \[[@sfy066-B98]\].

In contrast, if the 'two-prong' approach results in no further detection of proximal complement activation, then a genetic predisposition to the development of aHUS did not exist and a diagnosis of secondary aHUS can be made. Cessation of eculizimab therapy should be permissible without concern for recurrence ([Figures 3](#sfy066-F3){ref-type="fig"} and [4](#sfy066-F4){ref-type="fig"}).

![Clinical approach to a patient with the phenotypic picture of aHUS in whom TTP and STEC-E. Coli has been excluded. There are limited data to ascertain if the presence of aHUS in a complement amplifying disease is from an unmasking of a primary aHUS or from a complement storm in the setting of direct endothelial damage. \*DGKE aHUS has been reported to be both dependent and independent of the complement system.](sfy066f4){#sfy066-F4}

This construct will require the determination and validation of specific and sensitive markers for proximal and terminal complement activation. In this context, a recently described modified Hams test to distinguish between TTP and aHUS has been reported \[[@sfy066-B99]\]. Patients with aHUS have a positive modified Hams test. In theory, patients who have a phenotypic expression of aHUS arising from a complement storm and direct noncomplement-initiated damage to endothelia would have a negative modified Hams test when evaluated after a two-prong therapeutic approach, resulting in resolution of the inciting event and the attendant secondary complement activation. The functional assays reported by different laboratories all rely on serum or plasma and therefore are only able to evaluate CRPs such as CFH, CFI or mutations in C3 and CFB \[[@sfy066-B36], [@sfy066-B85], [@sfy066-B98]\]. As such, they are limited to evaluating fluid phase activators and inhibitors of complement. Further, highlighting the difficulty in ascertaining sensitive and interpretable serum, plasma or urine biomarkers of complement activation is the recognition that the pathogenesis of aHUS is ascribed to membrane (i.e. endothelial cell) activation and amplification of complement. Thus serum, blood and urine biomarkers of complement activity may not reflect what is occurring in the microenvironment on the cell membrane.

For now, however, in the absence of a specific biomarker for aHUS, and pending commercial availability and reliability of proximal and terminal complement activation testing, evaluation of the response of complement activation can only be obtained through university research testing.

CONCLUSION
==========

Complement-mediated aHUS is understood to result from dysregulation of membrane-bound activation of the AP of complement. Mutations in complement proteins are identified in ∼50--70% of patients. Whether refinements of present genetic testing procedures will identify new classes of mutations remain to be determined.

On occasion, the clinician encounters a patient with a TMA, consistent with a complement-mediated pathogenesis, in the setting of another established disease (e.g. GVHD and SLE). When the clinical picture fails to resolve or worsens despite ongoing aggressive therapy directed at the presenting illness or withdrawal of the suspected offending drug, consideration should be given to the diagnosis of a secondary aHUS or an unmasking of a primary aHUS. The addition of eculizimab to the treatment of the underlying disease has been reported to be effective in many but not all such patients. This two-prong therapeutic approach to the patient with a clinical picture of secondary aHUS is consistent with an abrogation of ongoing complement dysregulation arising from direct endothelial damage and profound complement activation induced by the underlying disease or disorder.

In contrast to primary aHUS, where primary dysregulation of the AP of complement exists and the duration of therapy is uncertain, a defined duration of anticomplement therapy in secondary aHUS should be sufficient.

The clinical paradigm presented in this review can allow the appropriate use of eculizimab in select patients with secondary aHUS while remaining sensitive and cognizant of the cost of this drug.
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